745 results on '"J. O’Shaughnessy"'
Search Results
2. P125 Neoadjuvant pembrolizumab + chemotherapy vs placebo + chemotherapy followed by adjuvant pembrolizumab vs placebo for early TNBC: surgical outcomes from the phase 3 KEYNOTE-522 study
3. Safety outcomes from monarchE: Phase 3 study of abemaciclib combined with endocrine therapy for the adjuvant treatment of HR+, HER-2-, node-positive, high risk, early breast cancer
4. Facial Expression Overrides Lumbopelvic Kinematics for Clinical Judgements about Low Back Pain Intensity
5. European Friends of the American Revolution
6. Index
7. Foreword
8. Cover
9. 8: This Deplorable Entanglement
10. Title Page, Copyright, Dedication
11. Color Gallery
12. Notes
13. 9: Idle Ramblers Incapable of Application
14. 10: This Athenaeum
15. 6: Useful Knowledge
16. 7: A Wall of Separation
17. 2: Enlighten the People
18. 4: We Shall Have Every Religious Man in Virginia against Us
19. 1: Feast of Reason
20. 5: The Academical Village
21. 3: My Single Anxiety in the World
22. Acknowledgments
23. The Illimitable Freedom of the Human Mind: Thomas Jefferson's Idea of a University
24. Multivalent Interactions Drive the Toxoplasma AC9:AC10:ERK7 Complex To Concentrate ERK7 in the Apical Cap
25. Loss of the Conserved Alveolate Kinase MAPK2 Decouples Toxoplasma Cell Growth from Cell Division
26. Role of Interfacial Conditions on Blast Overpressure Propagation Into the Brain
27. Modelling steroidogenesis: a framework model to support hypothesis generation and testing across endocrine studies
28. The Founding of Thomas Jefferson's University
29. Identification of Sertoli cell-specific transcripts in the mouse testis and the role of FSH and androgen in the control of Sertoli cell activity
30. Long-term efficacy and safety of addition of carboplatin with or without veliparib to standard neoadjuvant chemotherapy in triple-negative breast cancer: 4-year follow-up data from BrighTNess, a randomized phase III trial
31. Treatment Response With VRDN-001, a Full Antagonist Antibody to IGF-1 Receptor, in Thyroid Eye Disease (TED): Phase 1/2 Clinical Study
32. Toxoplasma ERK7 protects the apical complex from premature degradation
33. Cryo-tomography reveals rigid-body motion and organization of apicomplexan invasion machinery
34. Alternative (backdoor) androgen production and masculinization in the human fetus.
35. Relationship of transcriptional markers to Leydig cell number in the mouse testis.
36. Elevated Immune Gene Expression Is Associated with Poor Reproductive Success of Urban Blue Tits
37. The Clinician's Duty to Warn or Protect
38. Loss of a conserved MAPK causes catastrophic failure in assembly of a specialized cilium-like structure inToxoplasma gondii
39. 196P Efficacy and safety of first-line (1L) ribociclib (RIB) + letrozole (LET) in patients (pts) with de novo metastatic disease and late recurrence from (neo)adjuvant therapy (tx) in MONALEESA (ML)-2
40. 97P Efficacy and safety of the fixed-dose combination of pertuzumab and trastuzumab for subcutaneous injection in patients with HER2-positive early breast cancer: Long-term data from the PHranceSCa study
41. 198P Relationship of diarrhea and neutropenia events with outcomes in patients (pts) with metastatic triple-negative breast cancer (mTNBC) treated with sacituzumab govitecan (SG): Post hoc analysis from the phase III ASCENT study
42. 98P Real-world effectiveness and safety of neratinib in the extended adjuvant treatment of patients with HER2+ early breast cancer (eBC) in the United States community oncology setting
43. 201P Trilaciclib combined with sacituzumab govitecan (SG) in metastatic triple-negative breast cancer (mTNBC): Preliminary phase II results
44. The Evolution Of The Armored Force, 1920-1940
45. Matching adjusted indirect comparison of PFS & OS comparing ribociclib + letrozole vs palbociclib + letrozole as first-line treatment of HR+/HER2− ABC: Analysis based on updated PFS & final OS results of MONALEESA-2 & PALOMA-2
46. 169P Neoadjuvant pembrolizumab + chemotherapy followed by adjuvant pembrolizumab for treatment of high-risk, early-stage triple-negative breast cancer: A network meta-analysis
47. 135MO HRQoL with neoadjuvant pembrolizumab + chemotherapy vs placebo + chemotherapy, followed by adjuvant pembrolizumab vs placebo for early-stage TNBC: Results from KEYNOTE-522
48. 273TiP ACE-Breast-03: A phase II study patients with HER2-positive metastatic breast cancer whose disease is resistant or refractory to T-DM1, and/or T-DXd, and/or tucatinib-containing regimens treated with ARX788
49. Toxoplasma ERK7 defends the apical complex from premature degradation
50. FOREWORD TO THE REISSUE
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.